Mylan claims good Samaritan cause in FDA case over generic Lipitor
This article was originally published in Scrip
Mylan claims that its efforts to push the US FDA to decide on and make public its position on the status of Ranbaxy's ANDA for generic Lipitor (atorvastatin) and the Indian firm's potential six-month exclusivity period for its version of the Pfizer product are all in the larger good of industry.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.